Global Burns Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Burns treatment during 2019. Clinical development activities are being undertaken by more than 25 companies including Aegle Therapeutics, AlgiPharma AS, Alliance Pharma Plc, Amarantus Bioscience Holdings Inc, Anterogen Co Ltd and others.
A Significant contribution to the Burns pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Burns pipeline included 28 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Burns condition and increased access to investments is encouraging growth of Burns drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Burns drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Burns therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Burns pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Burns. Further, orphan drug status, fast track designation, grants awarded and other special status for Burns pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Burns pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Burns Pipeline candidates-
A Significant contribution to the Burns pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Burns pipeline included 28 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Burns condition and increased access to investments is encouraging growth of Burns drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Burns drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Burns therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Burns pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Burns. Further, orphan drug status, fast track designation, grants awarded and other special status for Burns pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Burns pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Burns Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Burns drugs
- Late phase: Phase 3 and in-approval Burns drugs
- Company overview
- Snapshot
- Burns therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Burns- Disease Overview
2.2 Burns- Pipeline Snapshot
2.3 Burns- Pipeline Drugs by Phase
2.4 Burns- Pipeline Drugs by Company
2.5 Burns- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Aegle Therapeutics Burns Drug Pipeline, H2- 2019
3.2 AlgiPharma AS Burns Drug Pipeline, H2- 2019
3.3 Alliance Pharma Plc Burns Drug Pipeline, H2- 2019
3.4 Amarantus Bioscience Holdings Inc Burns Drug Pipeline, H2- 2019
3.5 Anterogen Co Ltd Burns Drug Pipeline, H2- 2019
3.6 Bioharmony Therapeutics Inc Burns Drug Pipeline, H2- 2019
3.7 Biomendics LLC Burns Drug Pipeline, H2- 2019
3.8 CFM Pharma Holding BV Burns Drug Pipeline, H2- 2019
3.9 Destiny Pharma Plc Burns Drug Pipeline, H2- 2019
3.10 Energenesis Biomedical Co Ltd Burns Drug Pipeline, H2- 2019
3.11 GNT Pharma Co Ltd Burns Drug Pipeline, H2- 2019
3.12 Hypo-Stream Ltd Burns Drug Pipeline, H2- 2019
3.13 Madam Therapeutics BV Burns Drug Pipeline, H2- 2019
3.14 MallInckrodt Plc Burns Drug Pipeline, H2- 2019
3.15 MediWound Ltd Burns Drug Pipeline, H2- 2019
3.16 NeoMatrix Therapeutics Inc Burns Drug Pipeline, H2- 2019
3.17 Novion Technologies Inc Burns Drug Pipeline, H2- 2019
3.18 Phagelux Inc Burns Drug Pipeline, H2- 2019
3.19 Pluristem Therapeutics Burns Drug Pipeline, H2- 2019
3.20 Riptide Bioscience Inc Burns Drug Pipeline, H2- 2019
3.21 Roji Ltd Burns Drug Pipeline, H2- 2019
3.22 Se-cure Pharmaceuticals Ltd Burns Drug Pipeline, H2- 2019
3.23 Sephoris Pharmaceuticals LLC Burns Drug Pipeline, H2- 2019
3.24 Stemsynergy Therapeutics Inc Burns Drug Pipeline, H2- 2019
3.25 TGV Laboratories Inc Burns Drug Pipeline, H2- 2019
3.26 TreeFrog Therapeutics SAS Burns Drug Pipeline, H2- 2019
3.27 USV Pvt Ltd Burns Drug Pipeline, H2- 2019
3.28 viDA Therapeutics Inc Burns Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Burns- Phase 1 Drug Details
4.2 Burns- Phase 1 Drug Overview
4.3 Burns- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Burns- Phase 2 Drug Details
5.2 Burns- Phase 2 Drug Overview
5.3 Burns- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Burns- Phase 3 Drug Details
6.2 Burns- Phase 3 Drug Overview
6.3 Burns- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Burns- Pre-clinical Phase Drug Details
7.2 Burns- Pre-clinical Phase Drug Overview
7.3 Burns- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Burns- Disease Overview
2.2 Burns- Pipeline Snapshot
2.3 Burns- Pipeline Drugs by Phase
2.4 Burns- Pipeline Drugs by Company
2.5 Burns- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Aegle Therapeutics Burns Drug Pipeline, H2- 2019
3.2 AlgiPharma AS Burns Drug Pipeline, H2- 2019
3.3 Alliance Pharma Plc Burns Drug Pipeline, H2- 2019
3.4 Amarantus Bioscience Holdings Inc Burns Drug Pipeline, H2- 2019
3.5 Anterogen Co Ltd Burns Drug Pipeline, H2- 2019
3.6 Bioharmony Therapeutics Inc Burns Drug Pipeline, H2- 2019
3.7 Biomendics LLC Burns Drug Pipeline, H2- 2019
3.8 CFM Pharma Holding BV Burns Drug Pipeline, H2- 2019
3.9 Destiny Pharma Plc Burns Drug Pipeline, H2- 2019
3.10 Energenesis Biomedical Co Ltd Burns Drug Pipeline, H2- 2019
3.11 GNT Pharma Co Ltd Burns Drug Pipeline, H2- 2019
3.12 Hypo-Stream Ltd Burns Drug Pipeline, H2- 2019
3.13 Madam Therapeutics BV Burns Drug Pipeline, H2- 2019
3.14 MallInckrodt Plc Burns Drug Pipeline, H2- 2019
3.15 MediWound Ltd Burns Drug Pipeline, H2- 2019
3.16 NeoMatrix Therapeutics Inc Burns Drug Pipeline, H2- 2019
3.17 Novion Technologies Inc Burns Drug Pipeline, H2- 2019
3.18 Phagelux Inc Burns Drug Pipeline, H2- 2019
3.19 Pluristem Therapeutics Burns Drug Pipeline, H2- 2019
3.20 Riptide Bioscience Inc Burns Drug Pipeline, H2- 2019
3.21 Roji Ltd Burns Drug Pipeline, H2- 2019
3.22 Se-cure Pharmaceuticals Ltd Burns Drug Pipeline, H2- 2019
3.23 Sephoris Pharmaceuticals LLC Burns Drug Pipeline, H2- 2019
3.24 Stemsynergy Therapeutics Inc Burns Drug Pipeline, H2- 2019
3.25 TGV Laboratories Inc Burns Drug Pipeline, H2- 2019
3.26 TreeFrog Therapeutics SAS Burns Drug Pipeline, H2- 2019
3.27 USV Pvt Ltd Burns Drug Pipeline, H2- 2019
3.28 viDA Therapeutics Inc Burns Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Burns- Phase 1 Drug Details
4.2 Burns- Phase 1 Drug Overview
4.3 Burns- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Burns- Phase 2 Drug Details
5.2 Burns- Phase 2 Drug Overview
5.3 Burns- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Burns- Phase 3 Drug Details
6.2 Burns- Phase 3 Drug Overview
6.3 Burns- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Burns- Pre-clinical Phase Drug Details
7.2 Burns- Pre-clinical Phase Drug Overview
7.3 Burns- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
